Karin Welén

632 total citations
20 papers, 488 citations indexed

About

Karin Welén is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Karin Welén has authored 20 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 10 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Karin Welén's work include Prostate Cancer Treatment and Research (17 papers), Bone health and treatments (5 papers) and Hippo pathway signaling and YAP/TAZ (5 papers). Karin Welén is often cited by papers focused on Prostate Cancer Treatment and Research (17 papers), Bone health and treatments (5 papers) and Hippo pathway signaling and YAP/TAZ (5 papers). Karin Welén collaborates with scholars based in Sweden, France and United States. Karin Welén's co-authors include Jan‐Erik Damber, Heléne Gustavsson, Karin Jennbacken, Anna Linder, Christina Vallbo, Andreas Josefsson, Anders Olsson, Karin Larsson, J‐E. Damber and Tomas Leanderson and has published in prestigious journals such as Scientific Reports, Oncotarget and Molecular and Cellular Endocrinology.

In The Last Decade

Karin Welén

20 papers receiving 487 citations

Peers

Karin Welén

PRM

ONCOL

RNMI

Allen Saliganan United States

Bryce Lakely United States

Tatsuya Shimomura Japan

Ecaterina Ileana France

Lucia Trandafir Switzerland

Victoria Rimkunas United States

Xinhai Wan United States

Heléne Gustavsson Sweden

João D. Barros‐Silva Portugal

Adam Foye United States

Allen Saliganan United States

Karin Welén

202 ×0.8

PRM

263 ×1.2

275 ×1.6

ONCOL

181 ×1.2

38 ×0.6

RNMI

Citations per year, relative to Karin Welén Karin Welén (= 1×) peers Allen Saliganan

Countries citing papers authored by Karin Welén

Since Specialization

Citations

This map shows the geographic impact of Karin Welén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Welén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Welén more than expected).

Fields of papers citing papers by Karin Welén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Welén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Welén. The network helps show where Karin Welén may publish in the future.

Co-authorship network of co-authors of Karin Welén

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Welén. A scholar is included among the top collaborators of Karin Welén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Welén. Karin Welén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Freyhult, Eva, et al.. (2022). Osteoclasts directly influence castration-resistant prostate cancer cells. Clinical & Experimental Metastasis. 39(5). 801–814. 3 indexed citations

Damber, Jan‐Erik, et al.. (2021). The roles of RUNX2 and osteoclasts in regulating expression of steroidogenic enzymes in castration-resistant prostate cancer cells. Molecular and Cellular Endocrinology. 535. 111380–111380. 5 indexed citations

Bäck, Tom, Karin Jennbacken, Sture Lindegren, et al.. (2020). Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors. EJNMMI Research. 10(1). 10–10. 26 indexed citations

Linder, Anna, Karin Larsson, Karin Welén, & Jan‐Erik Damber. (2020). RGS2 is prognostic for development of castration resistance and cancer‐specific survival in castration‐resistant prostate cancer. The Prostate. 80(11). 799–810. 10 indexed citations

Josefsson, Andreas, Karin Larsson, Eva Freyhult, Jan‐Erik Damber, & Karin Welén. (2019). Gene Expression Alterations during Development of Castration-Resistant Prostate Cancer Are Detected in Circulating Tumor Cells. Cancers. 12(1). 39–39. 16 indexed citations

Linder, Anna, et al.. (2018). Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression. Scientific Reports. 8(1). 17259–17259. 25 indexed citations

Josefsson, Andreas, Karin Larsson, Marianne Månsson, et al.. (2018). Circulating tumor cells mirror bone metastatic phenotype in prostate cancer. Oncotarget. 9(50). 29403–29413. 23 indexed citations

Josefsson, Andreas, Anna Linder, Giacomo Canesin, et al.. (2017). Circulating Tumor Cells as a Marker for Progression‐free Survival in Metastatic Castration‐naïve Prostate Cancer. The Prostate. 77(8). 849–858. 25 indexed citations

Nilsson, Maria, Pontus Thulin, Jocelyn Céraline, et al.. (2015). Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis. Molecular and Cellular Endocrinology. 422. 182–191. 21 indexed citations

10.

Magnusson, Lisa U., et al.. (2015). Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment. The Prostate. 76(4). 383–393. 10 indexed citations

11.

Jennbacken, Karin, et al.. (2013). Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Clinical & Experimental Metastasis. 31(3). 269–283. 30 indexed citations

12.

Wang, Wanzhong, et al.. (2012). Midkine is associated with neuroendocrine differentiation in castration‐resistant prostate cancer. The Prostate. 73(6). 657–667. 19 indexed citations

13.

Jennbacken, Karin, Karin Welén, Anders Olsson, et al.. (2011). Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline‐3‐carboxamide tasquinimod (ABR‐215050). The Prostate. 72(8). 913–924. 44 indexed citations

14.

Gustavsson, Heléne, et al.. (2010). ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors. BMC Cancer. 10(1). 288–288. 20 indexed citations

15.

Jennbacken, Karin, Heléne Gustavsson, Michael Horn, et al.. (2009). The prostatic environment suppresses growth of androgen‐independent prostate cancer xenografts: An effect influenced by testosterone. The Prostate. 69(11). 1164–1175. 21 indexed citations

16.

Welén, Karin, et al.. (2008). Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts. Prostate Cancer and Prostatic Diseases. 12(1). 41–46. 30 indexed citations

17.

Gustavsson, Heléne, et al.. (2008). Differential expression of angiopoietin‐2 and vascular endothelial growth factor in androgen‐independent prostate cancer models. British Journal of Urology. 102(8). 1034–1039. 16 indexed citations

18.

Gustavsson, Heléne, Karin Jennbacken, Karin Welén, & Jan‐Erik Damber. (2007). Altered expression of genes regulating angiogenesis in experimental androgen‐independent prostate cancer. The Prostate. 68(2). 161–170. 33 indexed citations

19.

Jennbacken, Karin, Heléne Gustavsson, Karin Welén, Christina Vallbo, & Jan‐Erik Damber. (2006). Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. The Prostate. 66(15). 1631–1640. 46 indexed citations

20.

Gustavsson, Heléne, Karin Welén, & Jan‐Erik Damber. (2004). Transition of an androgen‐dependent human prostate cancer cell line into an androgen‐independent subline is associated with increased angiogenesis. The Prostate. 62(4). 364–373. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact